QBIO Stock Overview
A biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Q BioMed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.041 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | -99.00% |
| 3 Month Change | 0% |
| 1 Year Change | -99.80% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| QBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | -0.5% |
| 1Y | -99.8% | -6.4% | 23.2% |
Return vs Industry: QBIO underperformed the US Biotechs industry which returned -6.4% over the past year.
Return vs Market: QBIO underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| QBIO volatility | |
|---|---|
| QBIO Average Weekly Movement | 8,272.8% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: QBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: QBIO's weekly volatility has decreased from 16008% to 8273% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Denis Corin | www.qbiomed.com |
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer.
Q BioMed Inc. Fundamentals Summary
| QBIO fundamental statistics | |
|---|---|
| Market cap | US$145.00 |
| Earnings (TTM) | -US$1.91m |
| Revenue (TTM) | US$209.29k |
0.0x
P/S Ratio0.0x
P/E RatioIs QBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QBIO income statement (TTM) | |
|---|---|
| Revenue | US$209.29k |
| Cost of Revenue | US$221.90k |
| Gross Profit | -US$12.60k |
| Other Expenses | US$1.90m |
| Earnings | -US$1.91m |
Last Reported Earnings
Feb 28, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did QBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 09:48 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2023/02/28 |
| Annual Earnings | 2022/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Q BioMed Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Theodore O'Neill | Litchfield Hills Research, LLC |
| Scott Henry | Roth MKM |